Please login to the form below

Not currently logged in
Email:
Password:

AML

This page shows the latest AML news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

AML) in patients aged 15 and over. ... If approved, the addition of Mylotarg to standard chemotherapy will provide an important new treatment option for patients with AML who would typically be treated with chemotherapy alone.”.

Latest news

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    It’s not the first disappointment in the lirilumab programme. Earlier this year, the anti-killer cell immunoglobulin-like receptor (KIR) antibody flunked the EffiKIR trial in acute myeloid leukaemia (AML),

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    FDA fast-tracks Astellas' Rydapt rival. AML treatment gilteritinib is currently involved in four phase III trials. ... Benner concluded: “We are pleased that the FDA has acknowledged the urgent need for new therapies for FLT3+ AML patients.”.

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    Novartis gets EU nod for leukaemia drug Rydapt. The FLT3 inhibitor adds to its US approval in AML. ... The EMA has cleared Rydapt (midostaurin) for use alongside chemotherapy in patients with newly-diagnosed adults with AML whose cancer cells carry the

  • AbbVie and Roche plan Venclexta combo filings in leukaemia AbbVie and Roche plan Venclexta combo filings in leukaemia

    AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... this year for the drug as a combination treatment with low-dose

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    acute myeloid leukaemia (AML). ... The first patient to be treated in the AML trial - a 58-year-old woman - also developed CRS and capillary leak syndrome but was managed with drug therapy and symptoms had

More from news
Approximately 8 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML.

  • Deal Watch July 2016 Deal Watch July 2016

    Earlier this year Jazz completed its acquisition of Celator Pharmaceuticals, acquiring a late-stage product, Vyxeos, which targets AML, and the new agreement brings complementary products to Jazz's portfolio.

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... 2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell

  • Deal Watch May 2016 Deal Watch May 2016

    2, 000. Celator/ Jazz. Corporate acquisition. Acquisition for $30.25 per share brings Vyxeos [nano scale liposomal formulation of cytarabine /daunorubicin] for AML, completed P3.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Actinium appoints director of clinical operations Actinium appoints director of clinical operations

    Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our

  • Celgene promotes Karen Browne to haematology director Celgene promotes Karen Browne to haematology director

    She then relocated to Switzerland in March 2010, taking up the role of associate director of MDS and acute myeloid leukaemia (AML), and less than two years later was promoted to ... director with responsibility for overall MDS/AML marketing across Europe.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics